Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report.
about
Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infectionAutosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasiaAdjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot studyUS Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisMendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunitySalmonella as a model for non-cognate Th1 cell stimulationSuccessful fludarabine-based hematopoietic stem cell transplantation in a pediatric patient with idiopathic CD4+ lymphocytopeniaAdjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study.Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice.Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosisSix-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis.Two cases illustrating successful adjunctive interferon-γ immunotherapy in refractory disseminated coccidioidomycosis.Hemolysin as a virulence factor for systemic infection with isolates of Mycobacterium avium complex.Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent proteinT-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts.Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts.Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-gamma) pathway.Whipple's disease revisited.Activation of NKT cells protects mice from tuberculosis.Treatment of disseminated mycobacterial infection with high-dose IFN-γ in a patient with IL-12Rβ1 deficiency.Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation.Extensively drug resistant tuberculosis in a 7-year-old child with interferon-γ and interleukin-12 deficiency.Recent developments in the treatment of tuberculosis.NEMO is a key component of NF-κB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus.Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression.Inherited and acquired immunodeficiencies underlying tuberculosis in childhood.Effects of gamma interferon and nitric oxide on the interaction of Mycobacterium avium subsp. paratuberculosis with bovine monocytesIntractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria?Can innate immunity be enhanced to treat microbial infections?Genetic lessons learned from X-linked Mendelian susceptibility to mycobacterial diseases.X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production.Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease.Successful treatment of disseminated BCG in a patient with severe combined immunodeficiency.Idiopathic CD4 lymphocytopenia: a case of missing, wandering or ineffective T cells.A user-friendly, highly sensitive assay to detect the IFN-gamma secretion by T cells.Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches.A novel X-linked recessive form of Mendelian susceptibility to mycobaterial disease.Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease.Cytokine therapy of tuberculosis at the crossroads.
P2860
Q24322505-2A8F1ADA-59AE-4EF5-A9B9-87D6B2D1A849Q24634431-64771A66-20B0-4F71-BBE7-4B3E0BFE3BCBQ24795200-4FAE17A0-C648-4089-BBF5-B8F8025F9208Q26775974-29E35A01-AC32-41BB-9980-E52D223A60CCQ26862947-9D70203E-9338-4A01-8D74-47EC4F2BA923Q28082931-A0F16160-54CF-4D0D-8E1E-8D270EAB2BE9Q28288837-681391A0-EE57-495A-97F2-0D4BED65D256Q33319304-EDC3D7F1-3195-4D0B-9796-CCDAAEF87990Q33554688-7578BC41-8D73-42BC-AEB3-FBD90A563AF2Q33630442-8EE1CDC4-52B4-40F2-BC4A-CF91B67E0FEBQ33654669-23FD9B4B-0055-44D4-9D5C-FA846BB1D4E8Q33921735-61E0B935-8013-433C-AFD8-F7B2525A6558Q33958782-A52DCE62-4992-4C78-8007-D96D31B20737Q34001548-F94B1292-FC74-4C9B-A3CE-D58AE1C39256Q34002515-A813370A-53DF-4024-BDDC-B24DE2BAB76EQ34009414-E3E8D513-CFF6-49EF-98FD-8FA5DC4AFB93Q34022537-2308D528-BE51-4FE7-9018-5BAE59185E3EQ34077068-4823B966-2C87-4079-9550-97091544C794Q34182581-A77F6A8E-B481-45FC-9B53-DC9D3D05FC50Q34460558-8582EFB8-26F6-4994-8CB2-DD370789C2B2Q34481015-186FC7CD-6FC0-455A-ADF2-4C0A3C88143FQ34533402-ABF24253-C9BA-44FE-A066-2D023F602342Q35185753-195AC169-418D-4443-85B7-D9E3C5ADFF13Q35190204-0FE84FA1-DB7D-40BD-AA0D-FD17AD0443ABQ35372676-00362AA7-CBDC-4B45-8B6D-AC0D1A28D3A5Q35474954-5864116E-0AC5-4602-A295-7D1FDE2E7443Q35510477-33D87468-5B02-4F81-9152-AF1214CA54E2Q35546620-E4038C33-AB8D-41D3-A7AA-64BBBC6947F3Q35577180-D9A3DC24-728D-480E-89A5-64F1A0EBC9FEQ35777677-CA02723E-5D9B-4B23-A20A-B9B19C81EB80Q35860015-F08E3467-79C2-42E3-8AAA-1CE4A1194056Q36228741-2D6C407C-3D9B-41AE-9FB6-328399D27BEBQ36598807-0F39F7CB-3D55-4867-8C10-BB1C3367F2A8Q36628884-C4A2E71E-F310-42E5-AC8E-55439F017B95Q36633448-2A08F04A-E4A8-4143-9985-80EB2319BC25Q36662795-54129599-235E-465E-A90A-90F4368F79A7Q36839739-CED3BD3B-3290-4744-9768-726AD81EFCB0Q37004799-30FDC75C-D474-499B-A40D-F94F3AB89B0FQ37676737-8FFF1659-706E-45B5-B5BE-D3C95A37549BQ37754962-3D7833E8-A56D-4B2D-B7F2-3D8255AEBBB9
P2860
Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Treatment of refractory dissem ...... n gamma. A preliminary report.
@en
type
label
Treatment of refractory dissem ...... n gamma. A preliminary report.
@en
prefLabel
Treatment of refractory dissem ...... n gamma. A preliminary report.
@en
P2093
P1476
Treatment of refractory dissem ...... n gamma. A preliminary report.
@en
P2093
Eisenstein EM
Fleisher TA
Holland SM
P304
P356
10.1056/NEJM199405123301904
P407
P577
1994-05-01T00:00:00Z